HIV Medications: All 9 Drug Classes, Recommended Regimens & Cost (2026)

HIV is treated with antiretroviral therapy (ART) using FDA-approved medications from nine drug classes recognized by the U.S. Department of Health and Human Services (DHHS): NRTIs, NNRTIs, INSTIs, protease inhibitors, fusion inhibitors, CCR5 antagonists, CD4 post-attachment inhibitors, gp120 attachment inhibitors, and capsid inhibitors. The most commonly recommended first-line regimens in 2026 are Biktarvy, Triumeq, and Dovato — all single-tablet, once-daily options. Long-acting injectables like Cabenuva and Yeztugo now offer alternatives to daily pills for treatment and prevention.

Sources: NIH HIVinfo · DHHS Guidelines

The nine classes of HIV medications

HIV drugs are classified by the step in the viral life cycle they block. The DHHS guidelines recognize nine mechanistic classes of antiretroviral drugs. Understanding these classes helps explain why your regimen combines specific medications and why switching one drug doesn’t always mean switching the whole regimen.

NRTIs — Nucleoside Reverse Transcriptase Inhibitors

NRTIs provide defective building blocks that HIV needs to copy its genetic material. When the virus incorporates these faulty building blocks, it cannot finish making copies of itself. NRTIs form the backbone of nearly all HIV treatment regimens and were the first class of HIV drugs developed. Source: NIH HIVinfo.

NNRTIs — Non-Nucleoside Reverse Transcriptase Inhibitors

NNRTIs target the same enzyme as NRTIs (reverse transcriptase) but work differently — they bind directly to the enzyme and change its shape so it can no longer function. Both classes target reverse transcriptase, but NRTIs act as faulty building blocks the enzyme incorporates, while NNRTIs bind directly and disable it. Compared to older NNRTIs like efavirenz, doravirine has fewer neuropsychiatric side effects and a more favorable drug interaction profile.

INSTIs — Integrase Strand Transfer Inhibitors

INSTIs block the integrase enzyme HIV uses to insert its genetic code into human DNA. They are the cornerstone of modern HIV treatment and recommended as part of all preferred initial regimens in current DHHS guidelines. INSTIs are preferred because they combine high efficacy (over 90% viral suppression at 48 weeks in clinical trials), a high genetic barrier to resistance, fewer drug interactions than older classes, and a generally favorable side-effect profile. Current INSTIs: dolutegravir (DTG), bictegravir (BIC), cabotegravir (CAB), raltegravir (RAL), elvitegravir (EVG). Source: DHHS Guidelines.

Protease Inhibitors

PIs block the protease enzyme, which HIV needs to cut long protein chains into smaller pieces required to assemble new virus particles. Without functional protease, the virus produces immature, non-infectious copies. PIs are typically used with a pharmacokinetic enhancer (ritonavir or cobicistat) to boost their levels in the body. WHO’s 2026 updated guidelines confirm darunavir/ritonavir as the preferred PI when a PI-based regimen is needed. Source: WHO, January 2026.

Fusion Inhibitors

Fusion inhibitors work outside the cell by blocking HIV from physically fusing with and entering CD4 cells. They are used for treatment-experienced patients with multi-drug-resistant HIV. Enfuvirtide (Fuzeon) is the only approved drug in this class and requires twice-daily subcutaneous injection.

CCR5 Antagonists

CCR5 antagonists block the CCR5 coreceptor on the surface of CD4 cells, which some strains of HIV need to enter the cell. Maraviroc (Selzentry) is the only approved CCR5 antagonist. Before prescribing maraviroc, clinicians must perform a tropism test to confirm the patient’s HIV uses the CCR5 coreceptor — not the CXCR4 coreceptor or both. This class is used in specific clinical situations, not routine first-line treatment.

CD4 Post-Attachment Inhibitors

CD4 post-attachment inhibitors block HIV after it has attached to the CD4 receptor but before it can enter the cell. Ibalizumab-uiyk (Trogarzo) is the only approved drug in this class. It is a monoclonal antibody administered by intravenous infusion every two weeks, indicated for heavily treatment-experienced adults with multi-drug-resistant HIV who are failing their current regimen. FDA-approved in 2018.

gp120 Attachment Inhibitors

gp120 attachment inhibitors bind to the gp120 protein on the outer surface of HIV, preventing the virus from initially attaching to CD4 cells. Fostemsavir (Rukobia) is the only approved drug in this class — an oral medication taken twice daily, indicated for heavily treatment-experienced adults with multi-drug-resistant HIV. FDA-approved in 2020.

Capsid Inhibitors

Capsid inhibitors are the newest class of HIV drugs. They target the protein shell (capsid) that protects HIV’s genetic material. The first and only approved capsid inhibitor is lenacapavir (Sunlenca for treatment, Yeztugo for PrEP), developed by Gilead Sciences. Lenacapavir is unique because it interferes with multiple stages of the viral life cycle and has an extremely long half-life, enabling dosing as infrequently as every six months. Yeztugo was FDA-approved in June 2025 as a twice-yearly injectable PrEP option.

Recommended first-line regimens (DHHS 2025–2026)

The U.S. Department of Health and Human Services (DHHS) maintains the authoritative Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV, updated regularly based on new evidence. Current guidelines recommend the following INSTI-based regimens for most people starting HIV treatment for the first time.

Recommended initial regimens for most people

• Biktarvy (bictegravir + emtricitabine + tenofovir alafenamide) — one tablet, once daily, with or without food. The most prescribed HIV treatment in the U.S. as of 2026; high barrier to resistance and favorable tolerability.
• Triumeq (dolutegravir + abacavir + lamivudine) — one tablet, once daily; requires negative HLA-B*5701 test before starting. Not recommended for patients with hepatitis B coinfection.
• Dovato (dolutegravir + lamivudine) — one tablet, once daily; a two-drug regimen suitable for patients with HIV RNA below 500,000 copies/mL and no hepatitis B coinfection. Uses fewer drugs than traditional three-drug regimens.

Other recommended regimens for certain situations

• Cabenuva (cabotegravir + rilpivirine, injectable) — for virologically suppressed patients who prefer injections every one or two months instead of daily pills
• Delstrigo (doravirine + lamivudine + tenofovir disoproxil fumarate) — an NNRTI-based option when INSTIs cannot be used
• Symtuza (darunavir + cobicistat + emtricitabine + tenofovir alafenamide) — a PI-based option for situations where INSTIs and NNRTIs are not appropriate

Single-tablet regimens — comparison table

Single-tablet regimens (STRs) combine two or three HIV drugs from one or more classes into a single pill. They are preferred by most guidelines because of improved adherence. The following table compares the major STRs available in the U.S. as of 2026.

Abbreviations: BIC = bictegravir · DTG = dolutegravir · EVG = elvitegravir · DOR = doravirine · RPV = rilpivirine · DRV = darunavir · COBI = cobicistat · FTC = emtricitabine · 3TC = lamivudine · ABC = abacavir · TAF = tenofovir alafenamide · TDF = tenofovir disoproxil fumarate. Sources: NIH HIVinfo · DHHS Guidelines.

Long-acting injectable HIV medications

Long-acting injectables represent one of the most significant advances in HIV medicine, offering alternatives to daily pills for both treatment and prevention.

For treatment

Cabenuva (cabotegravir + rilpivirine, injectable) is the only FDA-approved long-acting injectable for HIV treatment. It is administered as two intramuscular injections by a healthcare provider every one or two months. Cabenuva is approved for adults who are already virologically suppressed on a stable oral regimen and have no history of treatment failure or resistance to cabotegravir or rilpivirine.

Sunlenca (lenacapavir, injectable) is the first capsid inhibitor approved for treatment, given as a subcutaneous injection every six months combined with other antiretrovirals. Sunlenca is specifically indicated for heavily treatment-experienced adults with multi-drug-resistant HIV.

For prevention (PrEP)

Yeztugo (lenacapavir, injectable) was approved by the FDA in June 2025 for HIV prevention (PrEP). It provides near-complete protection with just two injections per year, based on the landmark PURPOSE 1 and PURPOSE 2 clinical trials. Lenacapavir PrEP was named Science magazine’s 2024 Breakthrough of the Year. Source: Gilead/FDA.

Apretude (cabotegravir, injectable) is a bimonthly injectable PrEP option, requiring an injection every two months administered by a healthcare provider following an initial oral lead-in period.

Pre-Exposure Prophylaxis (PrEP) — medications for HIV prevention

PrEP is medication taken by HIV-negative individuals to prevent HIV infection. When taken as prescribed, PrEP is highly effective. As of 2026, PrEP is recommended by the CDC for anyone at substantial risk of HIV acquisition.

Side effects of HIV medications

Modern HIV medications are generally well tolerated, especially compared to earlier-generation drugs. However, all medications have potential side effects, and your clinician will monitor for specific concerns based on your regimen.

Common short-term side effects

When starting a new HIV regimen, some people experience initial side effects that typically resolve within the first two to six weeks. These may include nausea, diarrhea, headache, fatigue, dizziness, and difficulty sleeping. INSTI-based regimens (Biktarvy, Triumeq, Dovato) generally have the fewest side effects among current first-line options, which is one reason they are preferred by guidelines. If side effects persist beyond several weeks or are severe, talk to your clinician — a regimen change may be possible.

Weight gain and metabolic changes

Weight gain has emerged as one of the most discussed concerns in HIV treatment. Clinical data suggest that newer INSTI-based regimens — particularly those combining dolutegravir or bictegravir with tenofovir alafenamide (TAF) — are associated with greater weight gain than older regimens. This effect may disproportionately affect women and Black patients.

The DHHS guidelines include a dedicated section on this topic, noting that while the mechanism is not fully understood, contributing factors may include return to health after HIV suppression, effects of specific drugs on metabolic pathways, and the switch away from older agents like tenofovir disoproxil fumarate (TDF). Your clinician should monitor weight and metabolic markers (blood sugar, cholesterol) at regular intervals. Source: DHHS Guidelines.

Long-term monitoring

HIV medications require ongoing monitoring to ensure safety over years and decades of use. Your clinician will regularly check kidney function (especially with TDF-containing regimens), bone mineral density (particularly in postmenopausal women and older adults), liver function, lipid profiles, and blood glucose levels.

Drug resistance — what it is and how to prevent it

Drug resistance occurs when HIV mutates in ways that allow it to replicate even in the presence of antiretroviral medications. Resistance is one of the most important considerations in HIV treatment because it can limit future treatment options.

How resistance develops

Resistance typically develops when drug levels in the body are too low to fully suppress the virus but high enough to exert selective pressure — creating an environment where resistant mutations have an advantage. The most common cause is inconsistent adherence (missing doses), but resistance can also develop from suboptimal drug regimens, drug interactions that lower medication levels, or transmission of already-resistant virus from another person.

Resistance barrier and regimen choice

Different drugs have different barriers to resistance. Drugs with a high barrier to resistance require multiple mutations to become ineffective, making resistance harder to develop. This is one reason current guidelines prefer INSTIs like dolutegravir and bictegravir. Older INSTIs like raltegravir and elvitegravir have a lower resistance barrier. Protease inhibitors boosted with ritonavir or cobicistat also have a high barrier to resistance.

Resistance testing

The DHHS guidelines recommend resistance testing for all patients before starting treatment and when treatment failure occurs. Genotypic resistance testing identifies specific mutations in HIV that predict reduced susceptibility to certain drugs. This helps clinicians select an effective regimen and avoid drugs that will not work against your specific virus. Source: DHHS Guidelines.

Adherence — the best prevention for resistance

Taking your medication consistently — every dose, every day, on time — is the single most important thing you can do to prevent drug resistance. Strategies that may help include using a pill organizer, setting phone reminders, building medication into a daily routine, choosing a regimen that fits your lifestyle, and discussing long-acting injectable options like Cabenuva if daily pills are a barrier. If you are struggling with adherence, tell your clinician — there is no judgment, and there are solutions.

Drug interactions

HIV medications can interact with other prescription drugs, over-the-counter medications, supplements, and some foods. Drug interactions can reduce the effectiveness of your HIV treatment, increase side effects, or affect the levels of your other medications. Common categories of interactions include antacids and acid reducers (which can reduce absorption of rilpivirine and some INSTIs), certain antibiotics and antifungals, cholesterol-lowering statins, hormonal contraceptives, and herbal supplements like St. John’s wort (which can dramatically reduce levels of many HIV drugs).

Before starting any new medication, supplement, or herbal product, always tell your clinician and pharmacist that you take HIV medications. The DHHS maintains a comprehensive, searchable drug interaction database at ClinicalInfo.HIV.gov. The University of Liverpool also provides a widely used HIV drug interaction checker available for free online.

HIV medications and pregnancy

Antiretroviral therapy during pregnancy is essential to protect both the parent and the baby. With proper treatment, the risk of perinatal HIV transmission can be reduced to less than 1%. However, regimen choice may change during pregnancy. The DHHS maintains separate Perinatal Guidelines that address which medications are preferred, which should be avoided, and how dosing may need to be adjusted.

Dolutegravir-based regimens are currently recommended as preferred options during pregnancy based on extensive safety data. Earlier concerns about a possible association between dolutegravir and neural tube defects (from the Tsepamo study in Botswana) have been substantially mitigated by larger studies showing a very small absolute risk. Bictegravir has less pregnancy safety data, and some regimen adjustments may be needed. If you are pregnant, planning to become pregnant, or breastfeeding, discuss your HIV treatment with your clinician as soon as possible.

Pipeline — new HIV medications in development (2026–2027)

Several important new HIV medications and formulations are in late-stage clinical development. While none are yet approved, they represent the next generation of treatment and prevention.

HIV medication cost and how to get help

HIV medication list prices in the U.S. are among the highest in the world. However, what patients actually pay varies enormously based on insurance coverage, assistance programs, and pharmacy. The table below shows approximate list prices for reference — most patients pay significantly less.

Prices are approximate WAC (wholesale acquisition cost) per 30-day supply as of early 2026. Copay card amounts apply to commercially insured patients only — not Medicare, Medicaid, or other government insurance. In January 2026, CMS selected Biktarvy for Medicare price negotiations under the Inflation Reduction Act — the first HIV medication ever chosen. A negotiated Maximum Fair Price is expected January 1, 2028 for Medicare Part D beneficiaries. Source: Positively Aware.

Cost assistance programs

Most people living with HIV do not pay the full listed price. The following programs can significantly reduce or eliminate out-of-pocket costs.

• Manufacturer copay cards and PAPs — Gilead, ViiV, Merck, and Janssen all offer copay assistance for commercially insured patients and free medication for qualifying uninsured patients (see links in table above)
• Ryan White HIV/AIDS Program / ADAP — federally funded safety net providing medications and medical care; find your state program at NASTAD or locate a clinic at findhivcare.hrsa.gov
• 340B Drug Pricing Program — certain safety-net providers receive discounted drug prices; ask your clinic if they participate. HRSA 340B Program
• Nonprofit copay foundations — Patient Advocate Foundation · PAN Foundation · HealthWell Foundation
• Ready, Set, PrEP — free PrEP for uninsured individuals at HIV.gov
• Medicare Extra Help (Low-Income Subsidy) — reduces Part D costs for qualifying beneficiaries at SSA.gov

Undetectable = Untransmittable (U=U)

One of the most important messages in HIV medicine today is U=U: Undetectable = Untransmittable. This means that people living with HIV who take antiretroviral therapy and achieve and maintain an undetectable viral load (fewer than 200 copies/mL) have effectively no risk of sexually transmitting HIV to their partners.

U=U is supported by rigorous scientific evidence from three landmark studies — HPTN 052, PARTNER/PARTNER2, and Opposites Attract — that collectively observed zero linked HIV transmissions from virally suppressed partners across tens of thousands of sexual encounters. U=U is endorsed by the NIH, the CDC, and over 1,100 organizations in 105 countries.

This concept underscores why early treatment initiation and consistent adherence matter not only for individual health but also for prevention at the community level. Source: NIAID Treatment as Prevention.

Frequently asked questions

Authoritative resources

• HIVinfo.NIH.gov — NIH’s patient-facing HIV information, drug database, and fact sheets
• ClinicalInfo.HIV.gov — HHS treatment guidelines, drug interaction database, and clinical resources
• DHHS Drug Interaction Database — searchable tool for checking HIV drug interactions
• Liverpool HIV Drug Interaction Checker — University of Liverpool’s comprehensive interaction tool
• CDC HIV Nexus — CDC guidelines for screening, prevention, and care
• HIV.gov — Federal HIV resources, testing locator, and PrEP program information
• Find HIV Care (HRSA) — locate Ryan White clinics and testing sites
• NASTAD ADAP Watch — state-by-state ADAP access and eligibility tracking